Robert Goulart to Papillomaviridae
This is a "connection" page, showing publications Robert Goulart has written about Papillomaviridae.
Connection Strength
0.728
-
Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, Goulart R, Huang EC, Tabbara SO. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020 Jul - Aug; 9(4):291-303.
Score: 0.172
-
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis. 2015 Apr; 19(2):91-6.
Score: 0.121
-
Davis Davey D, Davey DD, Goulart R, Nayar R. 2013 statement on human papillomavirus test utilization [corrected]. Diagn Cytopathol. 2014 May; 42(5):449-52.
Score: 0.113
-
Davis Davey D, Goulart R, Nayar R. 2013 statement on human papillomavirus [corrected] test utilization. Acta Cytol. 2014; 58(2):113-6.
Score: 0.112
-
Davis Davey D, Goulart R, Nayar R. 2013 statement on human papillomavirus [corrected] test utilization. Cancer Cytopathol. 2014 Feb; 122(2):83-6.
Score: 0.111
-
Pantanowitz L, Hornish M, Cao QJ, Goulart RA. HPV data can be used as a cytopathology laboratory quality indicator. Diagn Cytopathol. 2010 Feb; 38(2):159-60.
Score: 0.084
-
Pantanowitz L, Florence RR, Goulart RA, Otis CN. Trichomonas vaginalis P16 Immunoreactivity in cervicovaginal Pap tests: a diagnostic pitfall. Diagn Cytopathol. 2005 Sep; 33(3):210-3.
Score: 0.016